avatar
Adenosine Therapeutics

    Charlottesville, VA, USA

    Founded January 1999

    2 Employees

    C Corporation

    Medical Facilities and Services, Pharmaceuticals

Key People

Robert Capon

Chairman & CEO

Joel Linden

Executive

Description
Through an in-license agreement with the University of Virginia Patent Foundation, ATL was granted exclusive, worldwide rights to the University's adenosine-related patent portfolio, including apadenoson, developed as Stedivaze, a cardiac stress agent for use in diagnosis of coronary artery disease. Stedivaze was shepherded by ATL to the end of Phase II development before ATL sold substantially all its assets to Clinical Data, Inc. (CLDA) in 2008. CLDA and its successors carried on development into late Phase III. Acquired by Clinical Data in 2008; operating status currently unknown.
Updates Feed

    Today

    • Note Lorem

      Public
    • Document Lorem

      document.pdf
      1
      Public
    • Announcement Lorem

      Public

Sign up to see more data and start a conversation.

Already a user? Sign in